Investors Home  >  Investor Relations
Briefcase Printed Materials Email Alerts Download Center snapshot RSS

Investor Relations

Ticker: CNAT
5.36 (+ 0.04)
Stock price graph

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Conatus Pharmaceuticals's financial performance into perspective.

View all »   RSSRecent Releases

May 7, 2015
Conatus Pharmaceuticals Reports First Quarter 2015 Financial Results and Program Updates

Apr 30, 2015
Conatus Pharmaceuticals to Report First Quarter 2015 Financial Results

View all »Events & Presentations

May 7, 2015
Conatus Pharmaceuticals First Quarter 2015 Financial Results
Webcast Listen to webcast

Apr 23, 2015
The International Liver Congress™ 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL)
PDF Press Release  172.9 KB   Add to Briefcase
PDF Poster #LP35: "A placebo-controlled, multicenter, double-blind, randomised, pharmacokinetic and pharmacodynamic trial of emricasan (IDN-6556) in subjects with acute-on-chronic liver failure (ACLF)"  238.8 KB   Add to Briefcase
PDF Poster #LP37: "A placebo-controlled, multicenter, double-blind, randomised trial of emricasan (IDN-6556) in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases."  199.1 KB   Add to Briefcase
PDF Poster #P0396: "Emricasan, a potent pan-caspase inhibitor, rapidly reduces caspase activity and biomarkers of apoptosis in patients with hepatic impairment but not in healthy volunteers: implications for safety, selectivity and mechanism of action."  156.6 KB   Add to Briefcase